GBIO Form 8-K: Press Release Furnished for Q2 2025 Results

Rhea-AI Filing Summary

Generation Bio Co. furnished a press release announcing its financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Form 8-K. The filing states the press release is being furnished rather than filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings except by specific reference. The Form 8-K itself does not include any financial figures, metrics, or narrative of the results; readers must consult Exhibit 99.1 for the actual numbers and commentary.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished as an exhibit; no figures in the Form 8-K, so immediate assessment is limited.

The company has met SEC disclosure formality by furnishing a press release with quarterly results as Exhibit 99.1. Because the Form 8-K explicitly states the release is furnished and not filed, it lacks Section 18 filing liability. The absence of financial data or metrics in the Form 8-K prevents any evaluation of performance or guidance impact from this filing alone.

Corporate Governance Expert

TL;DR: Procedural compliance confirmed; materiality cannot be judged from this filing without the attached press release.

Generation Bio followed standard practice by furnishing the press release and including the exhibit and interactive data cover page. The filing documents the administrative status of the disclosure (furnished vs. filed), which has legal implications, but it does not provide substantive financial or operational information. Determination of material impact requires review of Exhibit 99.1.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

Where are Generation Bio's (GBIO) Q2 2025 results disclosed?

The results are disclosed in a press release furnished as Exhibit 99.1 to this Form 8-K; the Form 8-K itself does not include the financial figures.

Does this Form 8-K include specific financial figures for the quarter ended June 30, 2025?

No. The Form 8-K states the press release is furnished and does not contain the financial figures or metrics within the filing itself.

Is the press release attached to the Form 8-K considered 'filed' with the SEC?

No. The filing explicitly states the press release is being furnished, not filed, and therefore is not subject to Section 18 liability.

What exhibit numbers are included with this Form 8-K?

The filing lists Exhibit 99.1 (the press release) and Exhibit 104 (the Inline XBRL cover page interactive data file).

Which quarter do the results cover in the disclosed press release?

The press release announces results for the quarter ended June 30, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 08/12/2025 - 04:10 PM Learn about SEC filing dates

0001733294false00017332942025-08-122025-08-12

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 12, 2025

Generation Bio Co.

(Exact Name of Registrant as Specified in Charter)

​

Delaware		001-39319		81-4301284
(State or Other Jurisdiction of Incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​

​

301 Binney Street Cambridge, MA		02142
(Address of Principal Executive Offices)	​	(Zip Code)

​

Registrant’s telephone number, including area code: (617) 655-7500

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

	​		​
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share	​	GBIO	​	Nasdaq Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Generation Bio Co. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

​

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release Issued by Generation Bio Co. on August 12, 2025.
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	GENERATION BIO CO.
Date: August 12, 2025	By:	/s/ Geoff McDonough
		Name: Geoff McDonough, M.D.
		Title: President and Chief Executive Officer

​

​

​